NCT03864185View on ClinicalTrials.gov

The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 28, 2019

Primary Completion Date

May 27, 2021

Study Completion Date

May 27, 2021

Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
BIOLOGICAL

Rituximab (genetical recombination)

Administer 375 mg/m2 of rituximab (genetical recombination) IV infusion once weekly for 4 doses.

OTHER

Placebo

Administer placebo IV infusion once weekly for 4 doses.

Trial Locations (4)

466-8560

Nagoya University Hospital, Nagoya

Unknown

Chiba University Hospital, Chiba

Kyushu University Hospital, Fukuoka

Yamaguchi University Hospital, Ube

Sponsors
All Listed Sponsors
collaborator

Japan Agency for Medical Research and Development

OTHER_GOV

collaborator

Zenyaku Kogyo Co., Ltd.

INDUSTRY

lead

Nagoya University

OTHER